Spliced integrated retrotransposed element (SpIRE) formation in the human genome
- PMID: 29505568
- PMCID: PMC5860796
- DOI: 10.1371/journal.pbio.2003067
Spliced integrated retrotransposed element (SpIRE) formation in the human genome
Abstract
Human Long interspersed element-1 (L1) retrotransposons contain an internal RNA polymerase II promoter within their 5' untranslated region (UTR) and encode two proteins, (ORF1p and ORF2p) required for their mobilization (i.e., retrotransposition). The evolutionary success of L1 relies on the continuous retrotransposition of full-length L1 mRNAs. Previous studies identified functional splice donor (SD), splice acceptor (SA), and polyadenylation sequences in L1 mRNA and provided evidence that a small number of spliced L1 mRNAs retrotransposed in the human genome. Here, we demonstrate that the retrotransposition of intra-5'UTR or 5'UTR/ORF1 spliced L1 mRNAs leads to the generation of spliced integrated retrotransposed elements (SpIREs). We identified a new intra-5'UTR SpIRE that is ten times more abundant than previously identified SpIREs. Functional analyses demonstrated that both intra-5'UTR and 5'UTR/ORF1 SpIREs lack Cis-acting transcription factor binding sites and exhibit reduced promoter activity. The 5'UTR/ORF1 SpIREs also produce nonfunctional ORF1p variants. Finally, we demonstrate that sequence changes within the L1 5'UTR over evolutionary time, which permitted L1 to evade the repressive effects of a host protein, can lead to the generation of new L1 splicing events, which, upon retrotransposition, generates a new SpIRE subfamily. We conclude that splicing inhibits L1 retrotransposition, SpIREs generally represent evolutionary "dead-ends" in the L1 retrotransposition process, mutations within the L1 5'UTR alter L1 splicing dynamics, and that retrotransposition of the resultant spliced transcripts can generate interindividual genomic variation.
Conflict of interest statement
JVM is an inventor on the patent: “Kazazian, H.H., Boeke, J.D., Moran, J.V., and Dombroski, B.A. Compositions and methods of use of mammalian retrotransposons. Application No. 60/006,831; Patent No. 6,150,160; Issued November 21, 2000.” JVM has not made any money from this patent and voluntarily discloses this information.
Figures






Comment in
-
Reading the tea leaves: Dead transposon copies reveal novel host and transposon biology.PLoS Biol. 2018 Mar 5;16(3):e2005470. doi: 10.1371/journal.pbio.2005470. eCollection 2018 Mar. PLoS Biol. 2018. PMID: 29505560 Free PMC article.
References
-
- Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, et al. Initial sequencing and analysis of the human genome. Nature. 2001;409: 860–921. doi: 10.1038/35057062 - DOI - PubMed
-
- Kazazian HH Jr., Moran JV. The impact of L1 retrotransposons on the human genome. Nat Genet. 1998;19: 19–24. doi: 10.1038/ng0598-19 - DOI - PubMed
-
- Ostertag EM, Kazazian HH Jr. Twin priming: a proposed mechanism for the creation of inversions in L1 retrotransposition. Genome research. 2001;11: 2059–65. doi: 10.1101/gr.205701 - DOI - PMC - PubMed
-
- Brouha B, Schustak J, Badge RM, Lutz-Prigge S, Farley AH, Moran JV, et al. Hot L1s account for the bulk of retrotransposition in the human population. Proc Natl Acad Sci U S A. 2003;100: 5280–5. doi: 10.1073/pnas.0831042100 - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources